Zynerba Pharmaceuticals (NASDAQ: ZYNE) and Advaxis (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.
This is a breakdown of current ratings and recommmendations for Zynerba Pharmaceuticals and Advaxis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zynerba Pharmaceuticals presently has a consensus target price of $14.63, indicating a potential upside of 51.40%. Advaxis has a consensus target price of $21.00, indicating a potential upside of 359.52%. Given Advaxis’ stronger consensus rating and higher probable upside, analysts clearly believe Advaxis is more favorable than Zynerba Pharmaceuticals.
Insider & Institutional Ownership
34.3% of Zynerba Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.1% of Advaxis shares are owned by institutional investors. 10.0% of Zynerba Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Advaxis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Zynerba Pharmaceuticals has a beta of 5.46, suggesting that its stock price is 446% more volatile than the S&P 500. Comparatively, Advaxis has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.
Valuation and Earnings
This table compares Zynerba Pharmaceuticals and Advaxis’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Zynerba Pharmaceuticals||N/A||N/A||-$28.66 million||($2.62)||-3.69|
|Advaxis||$14.01 million||13.40||-$93.95 million||($2.29)||-2.00|
Zynerba Pharmaceuticals has higher revenue, but lower earnings than Advaxis. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.
This table compares Zynerba Pharmaceuticals and Advaxis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Zynerba Pharmaceuticals beats Advaxis on 7 of the 12 factors compared between the two stocks.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
Advaxis Company Profile
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.